2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.03 Safety and Efficacy of AL2846 Combined with TQB2450 In NSCLC Patients with Previous PD-(L)1 Inhibitor Treated (NCT06116240)

P4.11E.03 Safety and Efficacy of AL2846 Combined with TQB2450 In NSCLC Patients with Previous PD-(L)1 Inhibitor Treated (NCT06116240)

Back to course

Pdf Summary

The study explores the safety and efficacy of the combination of AL2846 and TQB2450 in patients with non-small cell lung cancer (NSCLC) who previously received PD-(L)1 inhibitors and platinum-based chemotherapy. Conducted by multiple hospitals in China, the study accommodates patients with locally advanced or metastatic NSCLC. Enrolled individuals had an ECOG performance status of 0-1 and measurable tumor lesions per RECIST v1.1 criteria. <br /><br />The study administered TQB2450 at 1200 mg and AL2846 at 120 mg daily in 21-day cycles, aiming primarily to evaluate the overall response rate (ORR) and secondarily to assess progression-free survival (PFS), disease control rate (DCR), duration of response (DOR), and overall survival (OS).<br /><br />As of January 31, 2024, 44 patients were part of the study, with 39 evaluable for efficacy. Preliminary findings indicated an ORR of 25.6% (10 out of 39 patients), a median PFS of 5.72 months, a DCR of 94.9%, a median DOR of 5.54 months, and a median OS of 13.44 months. The patient cohort mostly consisted of males (86.36%) with a median age of 62.5 years. Patients displayed varying stages of cancer, with 43.18% at stage IVb. <br /><br />Safety assessments revealed that 11.4% of patients required dose reductions, with most adverse events being manageable. Common treatment-related adverse events (TRAEs) included increased ALT/AST levels (45.45%), hypothyroidism (40.91%), hypertension (36.36%), and hypoalbuminemia (34.09%).<br /><br />The study suggests that while treatment-related adverse events exist, the combination therapy shows potential clinical benefits in this patient group, providing a promising alternative for those who have exhausted other treatments like PD-(L)1 inhibitors and chemotherapy.

Asset Subtitle

Liuchun Wang

Meta Tag

Speaker Liuchun Wang

Topic Metastatic NSCLC – Immunotherapy

Keywords

NSCLC

AL2846

TQB2450

PD-(L)1 inhibitors

platinum-based chemotherapy

overall response rate

progression-free survival

treatment-related adverse events

China

RECIST v1.1